Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

UC Irvine researchers conducted a study to better understand the molecular basis of amyotrophic lateral sclerosis (ALS), a ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Prescribed use of anti-anxiety drugs, hypnotics and sedatives, or antidepressants was tied to a higher future risk of ...

Experimental drug Ulefnersen shows potential in halting and even reversing symptoms in patients with FUS- Amyotrophic lateral sclerosis (ALS) mutation One patient regained full motor function ...

Richter died at 57 on Monday, June 2, from amyotrophic lateral sclerosis, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, said her husband, Jim Eber. A ...

Corcept Therapeutics' dazucorilant failed the primary ALS trial goal but showed improved survival outcomes and a safe profile ...

Dr. Simrit Parmar, an associate professor in the College of Medicine at Texas A&M University and founder of the ...

Amyotrophic lateral sclerosis (ALS) is a progressive disease that causes severe weakness due to progressive degeneration of a specific set of motor nerves in the spinal cord. People with ALS will ...

Brainstorm tapped Minaris to manufacture NurOwn for its upcoming Phase 3b clinical trial testing the treatment for ALS.

It’s been nearly a year since Charlottesville lost one of its most respected pediatricians. At 65, he was diagnosed with a ...